Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
G Eminowicz, S Vaja, D Gallardo, C Kent, M Panades, T Mathew, A Anand, J Forrest, M Adusumalli, A Chan, A M Hacker, A Hackshaw, J A Ledermann, M McCormack
Author Information
G Eminowicz: University College Hospital NHS Trust, London, UK. Electronic address: gemmaeminowicz@nhs.net.
S Vaja: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
D Gallardo: Instituto Nacional de Cancerlogia, Mexico City, Mexico.
C Kent: University of Leicester NHS Trust, UK.
M Panades: United Lincolnshire Hospitals NHS Trust, UK.
T Mathew: Sheffield Teaching Hospitals NHS Trust, UK.
A Anand: Nottingham University NHS Trust, UK.
J Forrest: Royal Devon University Hospitals NHS Foundation Trust, UK.
M Adusumalli: South Tees Hospitals NHS Foundation Trust, UK.
A Chan: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
A M Hacker: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
A Hackshaw: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
J A Ledermann: Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK.
M McCormack: University College Hospital NHS Trust, London, UK.
AIM: Induction chemotherapy (IC) added to chemoradiation (CRT) in locally advanced cervical cancer (LACC) improves survival at the expense of adverse events (AEs), 99���% with IC/CRT vs 95���% CRT alone, 59���% vs 48���% G3/4 AEs. We investigated the impact of this on quality of life (QoL). METHODS: 500 women with FIGO 2008 stage IB1 node positive, IB2, II, IIIB and IVA cervical carcinoma were randomised to CRT alone or IC (6 weeks carboplatin AUC2 paclitaxel 80mg/m) followed by CRT. QoL questionnaires (EORTC QLQ-C30 v3, QLQ-CX24) were completed at baseline, D1 week 4 IC, D1 CRT, D1 week 3 CRT, 4 weeks post CRT and all follow up visits. Mixed modelling for repeated measures was used to compare the groups during trial treatment to 2 years follow up (adjusting for baseline). RESULTS: QoL (global health status, physical and social functioning) slightly worsened during IC and symptom experience slightly improved. Emotional functioning improved during IC. Peripheral neuropathy was slightly worse with IC/CRT. Fatigue and nausea/vomiting worsened from baseline to week 4 IC whilst pain and diarrhoea improved, consistent with reported AEs. Over the whole period, mean differences for these symptoms between the treatment groups was small and not clinically significant and resolved by 12-18 months. In all cases, mean score differences during trial treatment until 2 years post CRT showed only small differences (<5 units) not meeting the threshold for clinical relevance. CONCLUSION: IC added to CRT does not adversely impact QoL compared to CRT, either during IC, during CRT or later.
